First Tracks Biotherapeutics (TRAX) - Total Assets
Based on the latest financial reports, First Tracks Biotherapeutics (TRAX) holds total assets worth $290.58 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See First Tracks Biotherapeutics share price for real-time trading data and today's change.
First Tracks Biotherapeutics - Total Assets Trend (2023–2025)
This chart illustrates how First Tracks Biotherapeutics's total assets have evolved over time, based on quarterly financial data. Also see TRAX operating cash flow for how efficiently the company converts equity into cash flow.
First Tracks Biotherapeutics - Asset Composition Analysis
Current Asset Composition (December 2025)
First Tracks Biotherapeutics's total assets of $290.58 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how First Tracks Biotherapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore First Tracks Biotherapeutics working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: First Tracks Biotherapeutics's current assets represent 95.7% of total assets in 2025, an increase from 89.7% in 2023.
- Cash Position: Cash and equivalents constituted 72.1% of total assets in 2025, up from 8.1% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
First Tracks Biotherapeutics Competitors by Total Assets
Key competitors of First Tracks Biotherapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
First Tracks Biotherapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.74 | - | - |
| Quick Ratio | 8.74 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $256.29 Million | - | - |
First Tracks Biotherapeutics - Advanced Valuation Insights
This section examines the relationship between First Tracks Biotherapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.49 |
| Latest Market Cap to Assets Ratio | 4.53 |
| Asset Growth Rate (YoY) | -25.2% |
| Total Assets | $330.55 Million |
| Market Capitalization | $1.50 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values First Tracks Biotherapeutics's assets at a significant premium (4.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: First Tracks Biotherapeutics's assets decreased by 25.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for First Tracks Biotherapeutics (2023–2025)
The table below shows the annual total assets of First Tracks Biotherapeutics from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $330.55 Million | -25.20% |
| 2024-12-31 | $441.89 Million | -0.50% |
| 2023-12-31 | $444.11 Million | -- |
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more